Ra Capital Management, L.P. Acquires 13,008,546 Shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) Stock

Eliem Therapeutics, Inc. (NASDAQ:ELYM) Director Ra Capital Management, L.P. bought 13,008,546 shares of Eliem Therapeutics stock in a transaction dated Thursday, June 27th. The stock was acquired at an average price of $3.84 per share, with a total value of $49,952,816.64. Following the acquisition, the director now directly owns 23,521,757 shares of the company’s stock, valued at $90,323,546.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Eliem Therapeutics Trading Down 3.4 %

NASDAQ:ELYM opened at $6.81 on Wednesday. The business’s fifty day moving average price is $7.76 and its 200 day moving average price is $4.61. The firm has a market capitalization of $202.60 million, a price-to-earnings ratio of -12.85 and a beta of -0.33. Eliem Therapeutics, Inc. has a 1-year low of $2.35 and a 1-year high of $11.55.

Eliem Therapeutics (NASDAQ:ELYM) last issued its earnings results on Wednesday, May 15th. The company reported ($0.06) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Eliem Therapeutics stock. Cerity Partners LLC purchased a new stake in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 13,821 shares of the company’s stock, valued at approximately $37,000. Cerity Partners LLC owned approximately 0.05% of Eliem Therapeutics as of its most recent SEC filing. Institutional investors own 69.76% of the company’s stock.

Eliem Therapeutics Company Profile

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.